H.C. Wainwright analyst Oren Livnat lowered the firm’s price target on Pacira to $57 from $63 and keeps a Buy rating on the shares. After a challenging 2023, the Street is underappreciating Pacira’s EBITDA tailwinds going forward, which offers “dramatic stock upside potential,” the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on PCRX:
- Pacira price target lowered to $58 from $67 at RBC Capital
- Pacira price target lowered to $45 from $52 at Needham
- Pacira BioSciences Reports Third Quarter 2023 Financial Results
- Pacira lowers FY23 EXPAREL product sale view to $535M-$540M from $550M-$560M
- Pacira reports Q3 adjusted EPS 72c, consensus 79c
